江苏恒瑞医药股份有限公司关于获得药物临床试验批准通知书的公告

Group 1 - The company Jiangsu Hengrui Medicine Co., Ltd. has received approval from the National Medical Products Administration for clinical trials of HRS-6213 injection, which will be conducted shortly [1][2] - HRS-6213 injection is designed to specifically bind to tumor proteins, emitting positrons during metabolism, which are captured by PET scanners to generate high-resolution images for tumor diagnosis and treatment planning [2] - The total R&D investment for HRS-6213 injection has reached approximately 8.93 million yuan [2]